Table 1 Patient characteristics.
From: Individualized anemia management enhanced by ferric pyrophosphate citrate protocol
Variable | Mean (SD) or n (%); N = 93 (all patients) | Phase A N = 54 | Phase B N = 78 | Phase C N = 66 |
|---|---|---|---|---|
Age | 62.0 (15.3) | 62.9 (14.0) | 62.5 (14.7) | 62.0 (16.4) |
Male Gender | 46 (49.5%) | 28 (51.9%) | 41 (52.6%) | 32 (48.4%) |
Race | ||||
Caucasian/White | 26 (28.0%) | 17 (31.5%) | 21 (26.9%) | 17 (25.8%) |
African American/Black | 21 (22.6%) | 12 (22.2%) | 18 (23.1%) | 14 (21.2%) |
Latino/Hispanic | 35 (37.6%) | 21 (38.9%) | 31 (39.7%) | 25 (37.9%) |
Asian | 7 (7.5%) | 3 (5.6%) | 7 (9.0%) | 6 (9.1%) |
Other/Unknown | 4 (4.3%) | 1 (1.9%) | 1 (1.3%) | 4 (5.0%) |
Diabetes (Type 1 or Type 2) | 55 (59.1%) | 37 (68.5%) | 50 (64.1%) | 37 (56.1%) |
